Newsletter Tool

Today’s Big News

Jul 16, 2025

AstraZeneca’s AL amyloidosis drug fails to reduce mortality in phase 3 test

GSK telegraphs 'very limited number' of job cuts amid R&D investment spree

NIH fires exec amid probe into wife’s role in $3.3M contract: report

HHS terminates employees after Supreme Court allows reduction in force to proceed

Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm

Alphabet’s SandboxAQ teams up with Swiss biotech to develop mRNA cancer vaccine

Kezar sees hepatitis hold lifted, hints at resurrecting lupus program

Featured

AstraZeneca’s AL amyloidosis drug fails to reduce mortality in phase 3 test

By James Waldron

AstraZeneca’s plans to get an amyloidosis blockbuster drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a phase 3 study.

GSK telegraphs 'very limited number' of job cuts amid R&D investment spree

By Fraiser Kansteiner

With GSK kicking its R&D engine into high gear in recent years, a shuffling of the scientific priorities at the company is only natural. But for a small subset of staffers, that redistribution of resources will mean job cuts, even as GSK eyes major R&D investments on the horizon.

NIH fires exec amid probe into wife’s role in $3.3M contract: report

By Nick Paul Taylor

The National Institutes of Health has fired its chief operating officer amid a probe into whether his wife could have benefited from a $3.3 million contract, according to The Washington Post.

How do you get pharmaceutical treatments where they’re needed most?

Sponsored by Evernorth Specialty Services

Choosing the right specialty pharmacy partner is critical. Especially when you’re treating rare, chronic and complex conditions. You need a partner who delivers more than just logistics management, therapy fulfillment and generalized patient care.

HHS terminates employees after Supreme Court allows reduction in force to proceed

By Darren Incorvaia

The Department of Health and Human Services (HHS) is laying off certain employees who were notified months ago of the reduction in force (RIF) after the Supreme Court lifted a district court order blocking the layoffs, an agency spokesperson confirmed to Fierce Biotech.

Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm

By James Waldron

Seven months after pressing pause on its plans for its PKMYT1 inhibitor, Repare Therapeutics has found a partner to take the cancer drug forward.

Alphabet’s SandboxAQ teams up with Swiss biotech to develop mRNA cancer vaccine

By Gabrielle Masson

Alphabet spinoff SandboxAQ is teaming up with iOncologi to build a new mRNA vaccine for a common and aggressive brain tumor known as glioblastoma.

Kezar sees hepatitis hold lifted, hints at resurrecting lupus program

By James Waldron

The FDA has lifted one of the two clinical holds placed on Kezar Life Sciences’ zetomipzomib, leading the biotech to speculate on whether to reignite another program for the same drug that remains under hold.

Evestia Clinical and Atlantic Research Group merge to form global CRO

By Darren Incorvaia

A pair of CROs from opposite sides of the Atlantic Ocean are merging to form a global organization. Evestia Clinical and Atlantic Research Group are joining forces to bring clients expertise in oncology, immunology, neurology and late-stage clinical trials, according to a July 15 release.

Deerfield goes three for three with Triple Threat Communications buy

By Andrea Park

Fittingly enough, for its third acquisition in as many years, Deerfield Group has picked up Triple Threat Communications.

A million veterans gave DNA to aid health research. Scientists worry the data will be wasted

By Darius Tahir, Kaiser Health News

Researchers say they fear the VA's Million Veteran Program is in limbo, jeopardizing years of work in gathering genetic data, surveys and blood samples.

340B pulled $6.5B in drug rebates from Medicaid in 2024, PhRMA-backed report finds

By Dave Muoio

Of the $6.5 billion tally of ineligible rebate funds, $4.2 billion of missed managed care plan rebates is borne by the federal government and $2.3 billion is shouldered by state governments.

Fierce podcasts

Don’t miss an episode

Biopharma layoffs aren't letting up

Biopharma layoffs have held steady through mid-2025, and in this episode of "The Top Line," we dig into the numbers, closures and policy changes shaping the trend.

Whole health, whole new med school: Alice Walton’s vision comes to life in Arkansas

Teva’s CEO shares ‘Pivot to Growth’ progress

Resources

Whitepaper

Industry-backed, data-driven approaches to enhancing container closure integrity

This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance.

How Will US Policy Impact the Growth of UK Biotech?

Presented by Blue Matter, strategic consultants in the life sciences

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.